The aim of this research proposal is the development of gene therapy approaches to the treatment of AIDS based on the use of trans-dominant negative mutants of the HIV-1 regulatory protein Rev. Initially, we will attempt to optimize the trans-inhibitory properties of the rev mutants initially described by this laboratory by the phenotypic analysis of an extensive series of targeted mutations of rev. Subsequently, these mutants will be introduced into viral vector delivery systems suitable for infection of CD4+ T-cell lines, as well as primary human helper T-cells, primary human macrophages, and human hematopoietic stem-cell populations. At this stage, we intend to dedicate a significant effort to optimizing both the level of expression of the trans-dominants within the target cell populations as well as the achievement of viral vector titres sufficient for biological utility. In parallel, we will assess the ability of these viral vectors to protect various target cell populations against challenge by both cloned and primary isolates of HIV-1. If significant protection can be obtained in vitro using the derived viral vector systems, we intend to proceed, in collaboration with other laboratories that specialize in this area, to an initial test of in vivo efficacy using viral challenge to reconstituted SCID/Hu mouse chimeras. We believe that the experiments outlined in this proposal will allow a clear decision to be made on the eventual feasability of using trans-dominant variants of this HIV regulatory protein in the gene therapy of HIV infected individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI029821-04
Application #
3144730
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1990-08-01
Project End
1995-05-31
Budget Start
1993-06-01
Budget End
1994-05-31
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Benson, R E; Sanfridson, A; Ottinger, J S et al. (1993) Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med 177:1561-6
Malim, M H; Cullen, B R (1993) Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol 13:6180-9
Malim, M H; Freimuth, W W; Liu, J et al. (1992) Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 176:1197-201
Tiley, L S; Madore, S J; Malim, M H et al. (1992) The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev 6:2077-87
Cullen, B R; Garrett, E D (1992) A comparison of regulatory features in primate lentiviruses. AIDS Res Hum Retroviruses 8:387-93
Cullen, B R (1992) Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 56:375-94
Tiley, L S; Malim, M H; Tewary, H K et al. (1992) Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci U S A 89:758-62
Malim, M H; McCarn, D F; Tiley, L S et al. (1991) Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol 65:4248-54
Garcia-Blanco, M A; Cullen, B R (1991) Molecular basis of latency in pathogenic human viruses. Science 254:815-20